Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 16/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24827911 | 0.82 | CYP3A4 (0.35) | OGAPANK3 | |
| SCHEMBL20225831 | 0.80 | OGA (0.41) | OGAKDM4ENPC1RAB9ALMNA | |
| SCHEMBL11402241 | 0.80 | HRH4 (0.47) | OGAPANK3LMNAHTR3AHRH4 | |
| SCHEMBL19105574 | 0.80 | PANK3 (0.40) | OGAPANK3KDM4ENPC1RAB9A | |
| SCHEMBL13466910 | 0.80 | PANK3 (0.40) | OGAPANK3LMNA | |
| SCHEMBL19001135 | 0.79 | OGA (0.44) | OGAPANK3 | |
| SCHEMBL17037512 | 0.79 | SIGMAR1 (0.43) | OGAKDM4E | |
| SCHEMBL10140525 | 0.79 | PANK3 (0.41) | OGAPANK3KDM4ENPC1RAB9A | |
| SCHEMBL21025738 | 0.79 | HTR3A (0.36) | OGAKDM4ENPC1RAB9ALMNA | |
| SCHEMBL1505703 | 0.79 | PANK3 (0.41) | OGAPANK3KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | BTK, BLK, SYK | OGA 1689/4885PANK3 612/4885KDM4E 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.